JP2023012503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023012503A5 JP2023012503A5 JP2022172004A JP2022172004A JP2023012503A5 JP 2023012503 A5 JP2023012503 A5 JP 2023012503A5 JP 2022172004 A JP2022172004 A JP 2022172004A JP 2022172004 A JP2022172004 A JP 2022172004A JP 2023012503 A5 JP2023012503 A5 JP 2023012503A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cik nkt
- population
- nkt cells
- cik
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000581 natural killer T-cell Anatomy 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024202837A JP2025015816A (ja) | 2018-07-10 | 2024-11-21 | 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696131P | 2018-07-10 | 2018-07-10 | |
| US62/696,131 | 2018-07-10 | ||
| PCT/US2019/040145 WO2020014029A1 (en) | 2018-07-10 | 2019-07-01 | Generating cik nkt cells from cord blood |
| JP2021500737A JP7190022B2 (ja) | 2018-07-10 | 2019-07-01 | 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500737A Division JP7190022B2 (ja) | 2018-07-10 | 2019-07-01 | 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024202837A Division JP2025015816A (ja) | 2018-07-10 | 2024-11-21 | 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023012503A JP2023012503A (ja) | 2023-01-25 |
| JP2023012503A5 true JP2023012503A5 (enExample) | 2023-06-22 |
| JP7664207B2 JP7664207B2 (ja) | 2025-04-17 |
Family
ID=67551410
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500737A Active JP7190022B2 (ja) | 2018-07-10 | 2019-07-01 | 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 |
| JP2022172004A Active JP7664207B2 (ja) | 2018-07-10 | 2022-10-27 | 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 |
| JP2024202837A Pending JP2025015816A (ja) | 2018-07-10 | 2024-11-21 | 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500737A Active JP7190022B2 (ja) | 2018-07-10 | 2019-07-01 | 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024202837A Pending JP2025015816A (ja) | 2018-07-10 | 2024-11-21 | 臍帯血からのｃｉｋ ｎｋｔ細胞の作製方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11931382B2 (enExample) |
| EP (1) | EP3820994A1 (enExample) |
| JP (3) | JP7190022B2 (enExample) |
| KR (3) | KR102721222B1 (enExample) |
| CN (2) | CN119372142A (enExample) |
| AU (2) | AU2019300782B2 (enExample) |
| CA (1) | CA3105601C (enExample) |
| IL (2) | IL319500A (enExample) |
| WO (1) | WO2020014029A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023515887A (ja) * | 2020-03-04 | 2023-04-14 | バイオイクリプス セラピューティクス， インコーポレイテッド | 活性化免疫細胞を製造する方法 |
| WO2021178890A1 (en) | 2020-03-06 | 2021-09-10 | Sorrento Therapeutics, Inc. | Innate immunity killer cells targeting psma positive tumor cells |
| CN111690607B (zh) * | 2020-06-19 | 2022-02-18 | 珠海贝索细胞科学技术有限公司 | 一种高效杀伤细胞体外培养试剂盒及培养方法 |
| CN112251407A (zh) * | 2020-11-03 | 2021-01-22 | 广州康琪莱精准医疗科技有限公司 | 一种脐带血cik细胞的扩增培养方法 |
| CN114807044B (zh) * | 2021-04-30 | 2023-09-08 | 四川大学华西医院 | 一种具有高nkt细胞比例的car-cik细胞制备方法及应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5190556A (en) | 1991-03-19 | 1993-03-02 | O.B. Tech, Inc. | Cord cutter sampler |
| US5372581A (en) | 1993-07-21 | 1994-12-13 | Minneapolis Children's Services Corporation | Method and apparatus for placental blood collection |
| TR200001253T2 (tr) | 1997-11-06 | 2000-11-21 | Roche Diagnostics Gmbh | Tümöre özel antijenler |
| EP1117691A1 (en) | 1998-10-05 | 2001-07-25 | Ludwig Institute For Cancer Research | Methods for producing human tumor antigen specific antibodies |
| US7098008B2 (en) | 2000-04-25 | 2006-08-29 | Ic&G Do. Ltd. | Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use |
| CN1444648A (zh) * | 2000-06-06 | 2003-09-24 | 麒麟麦酒株式会社 | 扩增自然杀伤t细胞的方法 |
| EP1653977A2 (en) * | 2003-07-17 | 2006-05-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Treatment of disorders associated with natural killer t cells |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| US8012484B2 (en) * | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
| WO2011052638A1 (ja) | 2009-10-28 | 2011-05-05 | タカラバイオ株式会社 | サイトカイン誘導キラー細胞の製造方法 |
| US20130059379A1 (en) * | 2010-02-24 | 2013-03-07 | Ingo Schmidt-Wolf | Method for the generation of a cik cell and nk cell population |
| US20130189268A1 (en) | 2010-06-22 | 2013-07-25 | Precision Biologics, Inc. | Colon and pancreas cancer specific antigens and antibodies |
| ES2656414T3 (es) | 2010-09-08 | 2018-02-27 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| US9868774B2 (en) | 2011-10-20 | 2018-01-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD22 chimeric antigen receptors |
| KR20220166873A (ko) | 2012-08-13 | 2022-12-19 | 셀룰래리티 인코포레이티드 | 자연 살해 세포 및 그의 용도 |
| WO2014039523A1 (en) | 2012-09-04 | 2014-03-13 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| WO2015112793A2 (en) * | 2014-01-27 | 2015-07-30 | St. Jude Children's Research Hospital, Inc. | Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof |
| CN104017770B (zh) | 2014-06-23 | 2015-04-29 | 山东赛乐中德生物科技有限公司 | 一种利用糖脂制备cik细胞的方法 |
| TWI702290B (zh) * | 2015-04-07 | 2020-08-21 | 富禾生醫股份有限公司 | 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途 |
| CN106434552B (zh) * | 2015-08-13 | 2022-04-29 | 清华大学 | 新型nkt样细胞亚群及其治疗肿瘤的用途 |
| CN105176927B (zh) * | 2015-10-15 | 2019-01-18 | 丛秀丽 | 一种细胞毒性增强的高效靶向杀伤nk/cik细胞的制备方法 |
| CN106566807A (zh) * | 2016-10-21 | 2017-04-19 | 闾军 | 一种浓度梯度rhIL‑2依赖的iNKT细胞扩增方法及其应用 |
| CN106434556B (zh) * | 2016-11-22 | 2019-10-11 | 上海新长安生物科技有限公司 | 一种体外诱导扩增i型nkt细胞的方法 |
| EP3634437A4 (en) * | 2017-05-19 | 2020-11-18 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES |
| WO2021035078A1 (en) * | 2019-08-21 | 2021-02-25 | Akeso Therapeutics, Inc. | Type iii nkt cells and related compositions and methods |
| CN111172110B (zh) * | 2019-12-20 | 2022-04-22 | 中科细胞科技(广州)有限公司 | 一种脐带血cik细胞的培养方法 |
-
2019
- 2019-07-01 IL IL319500A patent/IL319500A/en unknown
- 2019-07-01 CA CA3105601A patent/CA3105601C/en active Active
- 2019-07-01 WO PCT/US2019/040145 patent/WO2020014029A1/en not_active Ceased
- 2019-07-01 JP JP2021500737A patent/JP7190022B2/ja active Active
- 2019-07-01 KR KR1020237030695A patent/KR102721222B1/ko active Active
- 2019-07-01 CN CN202411381099.4A patent/CN119372142A/zh active Pending
- 2019-07-01 KR KR1020247034929A patent/KR102778139B1/ko active Active
- 2019-07-01 AU AU2019300782A patent/AU2019300782B2/en active Active
- 2019-07-01 KR KR1020217003409A patent/KR102577954B1/ko active Active
- 2019-07-01 EP EP19750191.9A patent/EP3820994A1/en active Pending
- 2019-07-01 CN CN201980046254.8A patent/CN112424343B/zh active Active
- 2019-07-01 IL IL279924A patent/IL279924B2/en unknown
-
2022
- 2022-07-03 US US17/856,997 patent/US11931382B2/en active Active
- 2022-10-27 JP JP2022172004A patent/JP7664207B2/ja active Active
-
2024
- 2024-02-03 AU AU2024200673A patent/AU2024200673A1/en active Pending
- 2024-02-08 US US18/437,185 patent/US20240180967A1/en active Pending
- 2024-11-21 JP JP2024202837A patent/JP2025015816A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023012503A5 (enExample) | ||
| Cutler et al. | Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation | |
| Spitzer et al. | Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus–associated lymphoma: AIDS Malignancy Consortium study 020 | |
| JP2010507567A5 (enExample) | ||
| FI3377534T3 (fi) | Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää | |
| JP2012532624A5 (enExample) | ||
| IL317199A (en) | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| Fatima et al. | Allicin as an adjunct immunotherapy against tuberculosis | |
| Parisi et al. | Acute myelogenous leukemia: advances and limitations of treatment | |
| Qadir et al. | HIV-Plasmodium Co-infection: Malaria in AIDS patients. | |
| CA2942214C (en) | Combination therapy with double negative t-cells | |
| CN115362253A (zh) | 利用维奈托克增强t细胞的方法 | |
| Khwaza et al. | Strategies for delivery of antiviral agents | |
| Nakasone et al. | Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study | |
| Lefrère et al. | Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure | |
| Sakoda et al. | Recurrent Subcutaneous Sweet's Disease in a myelofibrosis patient treated with ruxolitinib before allogeneic stem cell transplantation | |
| Sood et al. | Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies | |
| Visani et al. | Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy? | |
| Xu et al. | Current status of allogeneic hematopoietic cell transplantation for MDS | |
| Kochupillai et al. | Fetal liver infusion in acute myelogenous leukaemia | |
| BALAMITHRA et al. | Role of Natural Killer Cells in Innate Immunity-A Review. | |
| Meneses-Sagrero et al. | Natural compounds combined with imatinib as promising antileukemic therapy: An updated review | |
| FREI III | children, with this approach. 14, 15 | |
| Castelli et al. | Safety and efficacy of frontline doxorubicin in combination with temozolomide and valproic acid for the treatment of pediatric malignant gliomas: results of a phase 2 study | |
| Lu | A Novel Immunotherapy Construct for ALL: STAR-T Cell Therapy for Relapsed/Refractory B-Cell ALL |